Autres langues Daxor Corporation NYSE

Actions

DXR

US2394671034

Fonds d'investissement à capital fixe

Marché Fermé - NYSE 22:30:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
11,01 ^USD	-3,34 %		-2,28 %	-25,36 %

31/08	Daxor Corporation publie ses résultats pour le semestre clos le 30 juin 2026	CI
30/07	Daxor lance un laboratoire d'analyse sanguine dans l'est du Kansas	MT

Autres langues

08/09	Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
01/09	Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
31/08	Daxor Corporation Reports Earnings Results for the Half Year Ended June 30, 2026
30/07	Daxor Launches Blood Testing Lab in Eastern Kansis
30/07	Daxor Corporation Initiates Outpatient Blood Volume Analysis Program in Kansas
30/07	Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
07/07	Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
02/06	Daxor Says Received US Patent for Remote Blood Volume Monitor Technology
02/06	Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
28/04	Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
27/04	5,061,267 Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 27-APR-2026.
08/04	Daxor Corporation Expands Customer Footprint With New BVA Program At High-Volume Ohio Cardiology Center
08/04	Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
26/03	Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
26/03	Daxor Corporation Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data
17/03	Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26
17/03	Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
10/03	Daxor Corporation Showcases New Portable Blood Volume Analyzer
10/03	Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
09/03	Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
04/03	Daxor Corporation Reports 2025 Fiscal Year Results, Operating Revenue Up 45%, Net Asset Value Rises to $9.07 per Share
03/03	Daxor Corporation CEO and President Michael Feldschuh provides corporate update in letter to shareholders
03/03	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
03/03	Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
02/03	Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2025